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1  |  INTRODUC TION
Psoriasis is a complex inflammatory skin disease, which is mainly char-
acterized by keratinocyte hyperproliferation and massive immune 
cell infiltration, primarily affecting the skin1 with a wide-ranging clin-
ical presentation.2 However, not only the skin can show differences 
between patients, but some patients have arthritis3,4 while others 
may have psoriasis-related other organ involvements.5 Risk in de-
veloping the disease is based on multiple genetic and environmental 
factors which differ in individuals and in different populations.6 
Pustular psoriasis, the acute systemic generalized form, the chronic 
localized palmoplantar pustulosis and the acrodermatitis continua 
of Hallopeau represent a distinct group and have been linked to in-
terleukin (IL)-36 receptor antagonist (IL36RN) mutations. Mutations 
were also found in that group in a gene encoding the adaptor protein 
1 complex subunit (AP-1 complex subunit sigma-3, AP1S3) and a ke-
ratinocyte nuclear factor κB adaptor protein (the caspase recruit-
ment domain-containing protein 14, CARD14).7 Guttate psoriasis is 
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Abstract
Current data suggest that tissue microenvironment control immune functions. 
Therefore, understanding the tissue environment in which immune activation occurs 
will enhance our capability to interfere with abnormal immune pathology. Here, we 
argue that studying the constitutively abnormal functions of clinically uninvolved pso-
riatic skin in patients with plaque type psoriasis is very important to better understand 
psoriasis pathobiology, because non-lesional skin provides the tissue environment in 
which the psoriatic lesion develops. A key question in psoriasis is what initiates the 
abnormal, uncontrolled immune activation in the first place and the answer may lie in 
the skin. In light of this concept, we summarize abnormalities at the dermal-epidermal 
junction region which shows a special “non-healing-like” micro-wound phenotype in 
the psoriatic non-lesional skin that may act as a crucial susceptibility factor in the 
development of the disease.
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associated with streptococcal pharyngitis and HLA-Cw6, the most 
strongly associated psoriasis susceptibility allele.8 Psoriasis stud-
ies, including our own studies, usually focus on the most frequent, 
dominant plaque type psoriasis phenotype. An inherently abnormal 
immune regulation, both in innate as well as in adaptive responses, 
undoubtedly plays a central role in disease pathogenesis.9 However, 
it is also clear that the immune pathology is strongly influenced by 
the tissue environment.10,11
An increasing body of evidence suggests that not only the le-
sional skin of patients is affected in psoriasis, but the seemingly 
healthy-looking non-lesional skin of patients contains disease-spe-
cific alterations as well. In 1995, Kadunce and Krueger suggested 
that in psoriasis the entire skin has the capacity to develop lesions, 
and control of expression is linked to a complex interaction of epi-
dermal, dermal and immune cells. They considered psoriatic kera-
tinocytes to have an inherent capacity for hyperproliferation and 
aberrant differentiation and advised to consider not only cytokines 
and growth factors, but also regulators of transcription, translation 
and modifications of cytokines and growth factors.12 Data suggest 
that the psoriatic non-lesional skin could represent an intermedi-
ate stage between the healthy and lesional skin. Alterations in the 
non-lesional skin can reveal predisposing factors for lesion devel-
opment and specific structural changes, or factors which help in the 
maintenance of the non-lesional stage.13
2  |  INFL AMMATION IN THE NON-
LESIONAL PSORIATIC SKIN
The number of several immune cell types are elevated in non-le-
sional skin, and the inducible T-cell co-stimulator, ICOS, a T-cell acti-
vation marker, is also detected.14 The characteristically sharp edges 
of psoriatic plaques are indicative of a very local, tissue-, if not cell-
dependent effect. Cytokine signalling plays a key role in the patho-
mechanism of psoriasis. In psoriatic plaques, Th17 cytokines (mainly 
the IL-17A) stimulate the production of antimicrobial peptides which 
activate inflammatory cells, thus sustaining the inflamed state in the 
psoriatic skin. A large-scale study highlights the psoriasis specific-
ity of IL-17A signature, the importance of cathelicidin (LL37) and an 
increase in foetal and other protein abundance, suggesting degrada-
tion deficiency.15 The presence of circulating LL37-specific T cells 
significantly correlates with disease activity.16 Dermal CD3+γδ T 
cells are the major source of IL-17A, and their number is increased in 
psoriatic skin.17–19 Meta-analysis on three gene array studies showed 
enhanced expression of IL-17 and IL-17 signature genes in non-le-
sional epidermis compared with normal. The transcription factor C/
EBPδ also showed elevated expression14 and it is believed to medi-
ate the IL-17 signalling and it could enhance the sensitivity of non-
lesional keratinocytes to IL-17 stimuli.20 Elevated expression of IL-22 
in non-lesional versus healthy skin is associated with an upregulation 
of antimicrobial peptides.14 In psoriasis, interferon-γ (IFNγ) is known 
to take part in the immune induction of the keratinocyte cell cycle 
progression.21 In the above-mentioned gene array, the expression 
level of IFNγ and the IFNγ-related genes also showed higher expres-
sion in non-lesional versus healthy skin. It is also interesting to note 
that some genes, which are known to mediate keratinocyte differ-
entiation processes, are also upregulated in the non-lesional skin.14 
Furthermore, proinflammatory mediators, namely IL-1α and IL-1β, 
have been reported to show lower expression level in non-lesional 
skin.22 According to a recent study, in the clinically resolved lesions 
epidermal tissue, resident memory T cells are retained in the tissue 
and can produce cytokines indicating a site-specific T cell–driven 
disease memory.23 Besides alterations in the resolved psoriatic skin, 
epidermal resident T cells in never-lesional skin from patients with 
psoriasis can trigger psoriasiform tissue responses.24 These changes 
in the non-lesional skin affect the professional and non-professional 
immune cells, and the expression levels of the different cytokines 
suggest an altered inflammatory state of the clinically asymptomatic 
skin.
3  |  SIGNS OF TISSUE STRESS IN 
PSORIATIC NON-LESIONAL SKIN
One of the first indications of the altered stress response of the non-
lesional skin is the Koebner phenomenon, which means that psori-
atic lesions can develop on non-lesional skin after various injuries.25 
Tape stripping is one standard method to induce mechanical stress 
on the epidermis which results in enhanced proliferation rate 26 and 
overexpression of transforming growth factor (TGF) alpha in the 
non-lesional vs. healthy epidermis.27
Previously, we compared the expression profiles of non-lesional 
psoriatic and healthy epidermis, and we identified a long non-cod-
ing RNA induced by stress which we named Psoriasis Susceptibility-
Related RNA gene induced by stress (PRINS). In our studies, tissue 
samples are taken from the trunk of healthy and plaque type psori-
atic individuals. Interestingly, PRINS is highly expressed in non-le-
sional psoriatic tissue, but not in healthy or psoriatic lesional 
epidermis.28 Later it was shown that PRINS can downregulate in-
flammation due to destabilization of IL-6 and the chemokine ligand 5 
(CCL-5, RANTES) messenger RNAs.29 Moreover, PRINS can act as an 
apoptotic function regulator by influencing interferon alpha induc-
ible protein 6 (G1P3) gene expression30 and by interacting with miR-
491-5p31 and nucleophosmin.32 Our data indicated that similar to 
other known stress induced factors,33 PRINS had a protective effect 
on cells. Enhanced PRINS production by non-lesional keratinocytes 
can alter the stress response of the non-lesional epidermis thereby 
contributing to the pathogenesis of psoriasis.34
Further evidence that demonstrates the altered stress/inflam-
matory state of the non-lesional skin is the elevated expression 
of the psoriasis-associated danger signal induced caspase recruit-
ment domain family member 18 (CARD18), which has a negative 
role in keratinocyte inflammatory signalling.35 Bioinformatic com-
parison of the gene expression profile of psoriatic non-lesional and 
healthy epidermis exposed to the same lymphokines suggested al-
tered regulation of cell morphology, development, cell death and 
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metabolism of small molecules and lipids in psoriatic non-lesional 
epidermis. Data suggest that differential regulation of IL-23A and 
IL-1β genes in keratinocytes of psoriatic patients are important in 
lesion development.36
4  |  ABNORMALITIES AT THE DERMAL-
EPIDERMAL JUNC TION (DEJ)  REGION OF 
PSORIATIC NON-LESIONAL SKIN
Cell-cell and cell-extracellular matrix contact abnormalities, such as 
the basement membrane (BM) abnormality at the DEJ, can result 
in cell-extrinsic stress and defense responses, that is a tissue level 
response, and although it involves innate immune responses, it is not 
equivalent to the classical acute inflammatory response (para-inflam-
mation).37 Para-inflammation is an adaptive response to stress and 
malfunction in tissues that develops for restoration of homeostasis. 
It is an innate response that can evolve into classic inflammation due 
to additional or persistent stress or malfunction. Para-inflammation 
relies mainly on tissue resident macrophages, and indeed activated 
macrophages was observed in non-lesional psoriatic tissue.38
Altered integrin-mediated adhesion of psoriatic keratinocytes 
can be seen not only in the lesional but also in non-lesional skin. The 
polarized distribution of α2β1, α3β1 and α6β4 integrins is lost, the 
β1 integrin subunit is localized to the basal surface of basal kerati-
nocytes and is in contact with the BM, while β4 integrin is detected 
all around basal and suprabasal keratinocytes.39 Furthermore, kerat-
inocytes in non-lesional epidermis overexpress the main fibronectin 
(FN) receptor α5β1 integrin compared with normal skin.39,40
In the BM of non-lesional psoriatic skin, discontinuous and un-
even laminin-1 distribution was observed.41 Compared with normal 
skin, both non-lesional and lesional skin lack the expression of lami-
nin-α1 and there is evidence that without α-chain, there is no distinct 
BM formation.42 In another study, gaps, folding and reduplication 
were described with collagen type-IV α1, α2 chains and laminin-α2, 
α5, β1 and γ1-chains.43 A synthetic C16 peptide (KAFDITYVRLKF) 
that deputizes the functional domain of the laminin-γ1-chain was 
shown to have an anti-inflammatory effect, including leucocyte in-
filtration reduction, in a rat acute allergic encephalomyelitis model 
suggesting an important role of the BM proteins in inflammation.44
Two major forms of FN exist, a soluble, found in the serum 
and synthetized by hepatocytes, and the so-called cellular form, 
synthetized by fibroblasts, epithelial cells and others.45 We found 
that as opposed to normal skin, in psoriatic non-lesional skin, there 
was serum FN present around basal keratinocytes, which could be 
explained by a leaky BM.40 In vivo, the alternatively spliced, extra 
domain A containing FN (EDA+FN) variant is poorly expressed in 
adult tissue; however, it is overexpressed in developing embryos, in 
tumors (it is also called oncofoetal fibronectin), and in highly pro-
liferating tissues, such as wounds. The exact regulation of EDA+FN 
splicing is not completely clear, but TGFβ1 is known to enhance 
EDA+FN production in wounded tissue.46 We have evidence that 
keratinocytes are able to produce FN and its EDA+ isoform, and 
psoriatic non-lesional keratinocytes are more readily capable of 
EDA+FN production in response to signals of activation compared 
with normal cells.47 We recently also reported that signal transducer 
and activator of transcription 1 (STAT1) negatively regulate both FN 
and EDA+FN expression in healthy fibroblasts and this regulation is 
compromised in fibroblasts derived from non-lesional psoriatic der-
mis. We observed that in the non-lesional skin, STAT1 activation was 
absent in tissues far away from lesions.48 This is in line with known 
alterations of psoriatic keratinocytes in the IFN—interferon regula-
tory factor-1—STAT1—suppressor of cytokine signalling-1 regulatory 
pathway.49,50 Recombinant EDA+FN, but not other recombinant FN 
domains, is known to activate human Toll-like receptor-4 (TLR4) in 
human embryonic kidney 293 cells. EDA stimulation of TLR4 was de-
pendent upon co-expression of MD-2, a TLR4 accessory protein.51 
This indicates a mechanism by which EDA-containing FN fragments 
promote an innate inflammatory response.
At the DEJ, α5β1 integrin can mediate FN-mediated proliferative 
signals and can help in the cell adhesion process as well.39,50 In addi-
tion, together with EDA+FN, α5β1 integrin is overexpressed by basal 
keratinocytes, when the BM is disrupted, for example at psoriatic 
non-lesional skin sites or in wounds52 and binding of α5β1 integrin 
to EDA+FN is a provisional anchoring mechanism.53 The recently 
discovered short laminin peptide C16, representing the laminin-γ1 
functional domain, targets the α5β1 integrin and could block the 
association of α5β1 integrin to FN, thus suppressing FN-mediated 
proliferative, cytoskeletal, and inflammatory responses in HaCat 
keratinocytes. Furthermore, in imiquimod-induced psoriasis-like 
mouse model, C16 could reduce epidermal hyperproliferation and 
immune cell infiltration.44
Recent evidence indicates further abnormalities at the DEJ in 
psoriatic non-lesional skin suggesting a key role of this site in the 
pathomechanism of psoriasis. We have previously described that the 
cartilage oligomeric matrix protein (COMP) is also overexpressed in 
the psoriatic non-lesional skin.54 COMP is a structural component of 
the healthy skin, and it provides the cohesion between the anchor-
ing plaques of the upper dermis and the BM.55 We found that COMP 
formed a continuous layer below basal keratinocytes in non-lesional 
skin and could interact with the α5β1 integrin and EDA+FN due to 
the disrupted distribution of the laminin-α1. In addition, COMP 
helps in the maintenance of the non-lesional state by suppressing 
the proliferation of keratinocytes via interaction with α5β1 integrin 
despite the overexpression of EDA+FN. COMP may also be involved 
in influencing keratinocyte proliferation through its direct interac-
tion with EDA+FN.54
Matrix metalloproteinases (MMPs) play an important role in the 
stability and homeostasis of the extracellular matrix (ECM).56 MMP-2 
has the ability to modify the ECM and the BM, as it contributes to 
cell migration and tissue remodelling and has several substrates in-
cluding type IV collagen, laminin-1 and FN.57,58 Both MMP-2 and tis-
sue inhibitor of matrix metalloproteinases (TIMP)-2 are elevated in 
non-lesional psoriatic skin.59 MMP-9 also showed higher expression 
in non-lesional versus healthy skin,14 and it shares similar functions 
with MMP-2.56
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5  |  PSORIATIC NON-LESIONAL SKIN 
E XHIBITS CHANGES THAT RESEMBLE 
WOUND HE ALING
Several studies have provided evidence that psoriasis demonstrates 
many characteristics of wound repair. Both lesional and non-lesional 
skin of individuals with psoriasis show significantly faster healing 
than skin of healthy individuals.60 Hyperproliferation of keratino-
cytes, infiltration of inflammatory cells and neovascularization are 
common processes both in wound repair and in psoriasis. Further 
similarities are in filaggrin, transglutaminase and involucrin expres-
sion in both conditions. Antimicrobial peptides and specifically 
the antimicrobial protein REG3A, which is largely responsible for 
keratinocyte proliferation and differentiation after skin injury, are 
expressed not only following skin injury, but also in psoriasis.61 
Keratin-1 and keratin-10 show reduced, while keratin-6 and kera-
tin-16 show increased expression in both conditions.62
Mechanisms similar to the wound healing process can also be 
observed in the psoriatic non-lesional skin. The EDA+FN and its re-
ceptor, the α5β1 integrin, is overexpressed not only in psoriasis, but 
also in wounded tissue.63–65 The level of COMP in normal healing 
wounds is minimal; however, in chronic non-healing wounds, such as 
venous leg ulcer, it is overexpressed,66 similar to its overexpression 
in non-lesional skin. High dose recombinant human COMP protein 
treatment results in a delay in the wound healing in an ex vivo wound 
healing model.54 The BM is also affected in regeneration of the tis-
sue following injury.67 In the wound bed, the BM is often not intact, 
similar to areas of non-lesional skin where the laminin layer within 
the BM is discontinuous and the EDA+FN, α5β1 integrin and COMP 
show elevated expression. It has long been known that fenestration 
of the BM is part of the lesion formation process in psoriasis68,69 and 
a soluble form of FN could infiltrate into the epidermis evolving a 
micro-wound stage.70,71
MMPs are also important factors in wound healing; however, 
they can negatively affect healing if they are not present in the 
appropriate amount.72,73 MMP-2 and MMP-9 play a crucial role in 
wound healing due to their ability to remodel the ECM. The MMP-2 
expression is linked with the expression of laminin-332 and in-
creased keratinocyte migration at the edge of acute wounds, while 
MMP-9 is expressed at the leading edges of migrating keratinocytes 
during wound closure.74 During wound healing, MMP-2 and the pro-
MMP-2 activator MT1-MMP59 create a fragment that triggers cell 
migration by cleaving the gamma-2 chain of laminin-332.74 In chronic 
skin wounds, or non-healing wounds, the balance between MMPs 
and TIMPs is disrupted, which results in a delayed or absent wound 
closure. In chronic wounds the level of TIMPs are decreased, while 
the activity of MMPs are upregulated and this imbalance influences 
the turnover of the ECM.72 The induction of MMP-2 and MMP-9 
occurs via the α3 chain of laminin-5.75 In contrast, elevated MMP-9 
is able to suppress the mobility of fibroblasts and keratinocytes76,77 
and this phenomenon can also lead to a delayed re-epithelization.78
Recently, we showed that in the psoriatic non-lesional skin, there 
is an overexpression of keratinocyte growth factor (KGF) and its 
receptor KGFR (also known as FGFR2), indicating the activation of a 
wound healing process. Tape stripping of the skin did not lead to any 
obvious changes in α5 integrin, EDA+FN, KGF or KGFR expression or 
distribution at 24 and 48 h after tape stripping in non-lesional skin, 
while in the healthy controls a slight increase in all protein expres-
sion was detected based on immunostaining.48 KGF is known for its 
effect on keratinocyte proliferation and differentiation, and since it 
is not present in normal skin, but is induced in wound healing, it is 
regarded as a major player in the wound healing processes of epithe-
lial tissues.79 KGF in the skin is produced mainly by fibroblasts, but 
through the release of IL-1, keratinocytes induce KGF expression and 
release in fibroblasts.80 In an in vitro co-culture composed of kerati-
nocytes and fibroblasts, Jun and JunB antagonistically regulated the 
synthesis of fibroblast-derived KGF and GM-CSF.81 Psoriatic kerat-
inocytes derived from non-lesional epidermis produce significantly 
higher proinflammatory IL-1 in the presence of IL-17, compared with 
healthy skin keratinocytes, indicating an intrinsic feature of psoriasis 
epithelium.22
6  |  BULLOUS PEMPHIGOID AND 
PSORIA SIS
The coexistence of autoimmune bullous diseases, particularly the 
anti-laminin-γ1 (p200) pemphigoid, has been well documented in 
psoriasis.82 Autoimmune diseases are characterized by autoantibod-
ies, and autoreactive T cells specific for self-antigens. How exactly 
they contribute to any given pathological process is not always clear, 
and some may not play any role in disease pathology, they may only 
reflect abnormal processes taking place in tissues.83
Data indicate that protein complexes that are formed when cells 
are under stress could possess immunological features that can mod-
ulate the host's immune response and induce autoantibody produc-
tion. In the psoriatic non-lesional tissue, abnormal BM proteins may 
expose novel epitopes to immune cells and this, together with other 
immune activating factors, can induce autoantibody formation.84 It is 
presently not completely understood how much autoimmunity con-
tributes to psoriasis, and although no particular autoantibody could 
be linked to the disease so far, one cannot rule out the possibility 
that autoantibodies may participate in the maintenance of chronic 
inflammation. Homology between the streptococcal M-protein and 
keratin 17 raises the possibility of molecular mimicry taking place.85 
Indeed, cross-reactive CD8+ T cells can be detected in patients with 
psoriasis, especially in patients with HLA-Cw*0602.86 Circulating 
LL37-specific T cells correlates with disease activity 16 and ADAMTS-
like protein 5 was also proposed in psoriasis as an autoantigen that 
can contribute to the pathogenesis.87
7  |  CONCLUSIONS AND PERSPEC TIVES
Here, we propose that the seemingly normal looking skin of psoriatic 
patients represents a balanced, “non-healing-like” micro-wounded 
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skin phenotype mainly due to its structural abnormalities (Figure 1). 
Environmental factors (infection, wounding etc.) can easily tip the 
tissue out of its abnormal, but still visibly balanced state and induce 
an overt wound reaction (lesional skin). The keratinocyte prolifera-
tion rate in the clinically uninvolved epidermis of psoriatic patients 
is almost the same, as in the healthy epidermis26 despite the overex-
pression of KGF and its receptor,48 but, the psoriatic non-lesional ke-
ratinocytes are more sensitive to stress36 and proliferative signals21 
and the non-lesional skin shows a special para-inflammation state.37 
An intact DEJ region below the basal keratinocytes is crucial to the 
functional integrity of the skin. Abnormalities of the BM zone within 
the DEJ will have an effect both on the dermis and the epidermis.67
In the psoriatic non-lesional skin, the laminin layer within the BM 
is disrupted,41–43 EDA+FN is overexpressed47,88 and the expression 
of its receptor, the α5β1 integrin, on the surface of basal keratino-
cytes is also elevated without any observed hyperproliferation.39,40 
COMP could be one component, which despite these alterations 
can restrain the proliferation of basal keratinocytes and help to 
maintain the uninvolved, non-hyperproliferative phenotype of the 
non-lesional psoriatic skin.54 MMPs and their inhibitors may play 
an essential role in the regulation of the ECM proteins in the DEJ 
region.56 MMP-2 and MMP-9 overexpression in non-lesional psori-
atic skin14,59 suggest a potential connection with the altered laminin 
layer within the BM.
Wound healing on surfaces in direct contact with the external 
environment is tied to innate immune functions, because an intact 
barrier is essential for defending the body against microbes and 
other damaging environmental factors. Barrier tissues are highly 
equipped with numerous machineries to respond to noxa, and as 
suggested by Matzinger et al., they control immune functions.89 
Barrier dysfunction is not unique to psoriasis; other chronic in-
flammatory skin diseases are known to have various structural 
defects in the epidermis. These structural abnormalities may 
be inherent to the tissue (e.g., mutations in the gene encoding 
F I G U R E  1  Micro-wounds at the dermal-epidermal junction in psoriatic non-lesional skin. Schematic representation of (A) healthy and (B) 
psoriatic non-lesional skin. The incompleteness of the basement membrane and elevated cartilage oligomeric matrix protein level indicates 
the “non-healing-like” micro-wounds at the dermal-epidermal junction region of the non-lesional skin. These sites are labelled with black 
arrowheads. Framed areas show enlarged regions. Straight lines indicate direct, and dashed lines indicate partial relationship between 
the components. Literature data indicate potential relationship between the dotted line marked components. Red arrows represent the 
elevated expression of the proteins. (Abbreviations: BM, basement membrane; COMP, cartilage oligomeric matrix protein; DEJ, dermal-
epidermal junction; EDA+FN, fibronectin splice variant containing the extra domain A; FGFR2, fibroblast growth factor receptor 2; KGF, 
keratinocyte growth factor; MMP2, matrix-metalloproteinase 2; MMP9, matrix-metalloproteinase 9; TIMP2, tissue inhibitor of matrix 
metalloproteinases 2.)
6  |    BOZÓ et al.
filaggrin in atopic dermatitis)90 or induced by inflammation (e.g., 
lichen planus or drug induced reactions where basal keratinocytes 
are destroyed by cytotoxic T cells).91 The nature of the barrier 
dysfunction (e.g., abnormal differentiation of keratinocytes, tight 
junction, desmosomal, hemi-desmosomal deficiency) and the na-
ture of the dominant inflammation characterize the disease. For 
example, data suggest that atopic dermatitis is primarily an IL-13 
dominant disease, while in psoriasis the dominant immune reac-
tion is polarized towards the IL-17 response.92 In the chronic phase 
of inflammation common features of the wound healing immune 
response may be seen, such as in atopic dermatitis, where in the 
chronic phase of the disease a prominent activation of skin barrier 
repair signature can be detected in transcriptomic profiling using 
RNA-sequencing.93
Understanding the contribution of the tissue factors in the path-
omechanism of psoriasis will be essential to design therapies that 
give longer term relief from the disease than presently available 
treatments.
If, as indicated by our current knowledge, psoriasis is indeed ge-
netically determined, the non-lesional tissue is the place to look for 
the primary effects of the inherent susceptibility factors. In future 
studies of the non-lesional psoriatic tissue, it will be important to 
better characterize the investigated tissue samples. HLA-Cw*0602 
association, previous lesional versus never lesional status and sever-
ity of the disease based on PASI scores may influence the structural 
changes and its importance in disease pathophysiology.
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